Peregrine Pharmaceuticals (PPHM) : Analyst Rating Update

Peregrine Pharmaceuticals (PPHM) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 3 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Peregrine Pharmaceuticals (PPHM) : 3 Wall Street analysts covering Peregrine Pharmaceuticals (PPHM) believe that the average level the stock could reach for the short term is $1. The maximum price target given is $2 and the minimum target for short term is around $1, hence the standard deviation is calculated at $0.5.

Peregrine Pharmaceuticals (NASDAQ:PPHM): The stock opened at $0.38 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.39 for the day. The stock traded down to $0.37 during the day, due to lack of any buying support eventually closed down at $0.38 with a loss of -2.29% for the day. The stock had closed at $0.38 on the previous day. The total traded volume was 590,253 shares.

The company shares have dropped -69.11% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $1.38 and the one year low was seen on May 9, 2016. The 50-Day Moving Average price is $0.42 and the 200 Day Moving Average price is recorded at $0.61.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.